Form 4: Cue Biopharma CBO Granted 125,000 Stock Options

Cue Biopharma's Chief Business Officer, Lucinda Warren, was granted 125,000 stock options with an exercise price of $0.72, exercisable one year from the grant date.

Summary

• Lucinda Warren, Chief Business Officer of Cue Biopharma, Inc. (CUE), acquired 125,000 stock options.
• The options have an exercise price of $0.72 per share.
• The grant date for these options was September 29, 2025.
• The options become fully exercisable on the first anniversary of the grant date, which is September 29, 2026.
• The expiration date for these options is September 28, 2035.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned transaction.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is generally a neutral to slightly positive event, indicating executive retention and alignment of interests, but it does not provide direct insight into operational performance or financial health.

Positives

• The grant of stock options to a key executive like the Chief Business Officer can align management's interests with shareholder value.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned and transparent acquisition of equity.

Future Outlook

NA

Industry Context

Insider equity grants, such as stock options, are a common practice in the biotechnology and pharmaceutical industry to incentivize and retain key executives, aligning their long-term interests with the company's performance and shareholder value creation.

Stakeholder Impact

• Shareholders: Potential for increased alignment of executive interests with shareholder value, as the CBO's compensation is tied to stock performance.
• Employees: May signal stability in executive leadership and standard compensation practices.

Key Dates

Keywords

Cue Biopharma, CUE, Stock Option, Form 4, Insider Transaction, Lucinda Warren, Chief Business Officer, Equity Grant, Rule 10b5-1